Research Topics
| Michael R McDevittSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Targeted alpha particle immunotherapy for myeloid leukemiaJoseph G Jurcic
Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
Blood 100:1233-9. 2002..This study demonstrates the safety, feasibility, and antileukemic effects of (213)Bi-HuM195, and it is the first proof-of-concept for systemic targeted alpha particle immunotherapy in humans...- Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primatesMatthias Miederer
Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Nucl Med 45:129-37. 2004..However, the 3 alpha-emitting daughter elements generated have the potential for significant toxicity as these nuclides are no longer bound to the carrier IgG... - Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubesMichael R McDevitt
Molecular Pharmacology and Chemistry Department, Departments of Medicine and Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Nucl Med 48:1180-9. 2007..We hypothesized that novel prototype nanostructures consisting of biologics, radionuclides, fluorochromes, and CNT could be synthesized and designed to target tumor cells... 
PET imaging of soluble yttrium-86-labeled carbon nanotubes in miceMichael R McDevitt
Molecular Pharmacology and Chemistry Department, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
PLoS ONE 2:e907. 2007....- Efforts to control the errant products of a targeted in vivo generatorJaspreet Singh Jaggi
Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer Res 65:4888-95. 2005..0001). Metal chelation, diuresis with furosemide or chlorothiazide, and competitive metal blockade may be used as adjuvant therapies to modify the renal accumulation of 225Ac daughters... - Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expressionAse M Ballangrud
Memorial Sloan Kettering Cancer Center, New York, New York, USA
Clin Cancer Res 10:4489-97. 2004..225)Ac has a 10-day half-life and a decay scheme yielding four alpha-particles... - Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneysJaspreet Singh Jaggi
Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Int J Radiat Oncol Biol Phys 64:1503-12. 2006..We attempted to modify pharmacologically, the functional and morphologic changes in mouse kidneys after injection with the actinium ((225)Ac) nanogenerator, an in vivo generator of alpha- and beta-particle emitting elements... - Selective alpha-particle mediated depletion of tumor vasculature with vascular normalizationJaspreet Singh Jaggi
Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
PLoS ONE 2:e267. 2007..Alpha particles are extraordinarily potent, short-ranged radiations with geometry uniquely suitable for selectively killing neovasculature... 
Synthesis and biodistribution of oligonucleotide-functionalized, tumor-targetable carbon nanotubesCarlos H Villa
Molecular Pharmacology and Chemistry Program and Departments of Medicine and Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Nano Lett 8:4221-8. 2008..Appended RGD ligands allowed for specific binding to tumor cells in a flow cytometric assay. The techniques employed should enable the synthesis of multifunctional SWNT capable of self-assembly in biological settings...- Paradoxical glomerular filtration of carbon nanotubesAlessandro Ruggiero
Departments of Medicine, Radiology, Molecular Pharmacology and Chemistry or the Molecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Proc Natl Acad Sci U S A 107:12369-74. 2010.... - Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughtersJaspreet Singh Jaggi
Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Am Soc Nephrol 16:2677-89. 2005..These findings are dissimilar to those seen after gamma or beta irradiation of kidneys... - Enhanced retention of the alpha-particle-emitting daughters of Actinium-225 by liposome carriersStavroula Sofou
Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Bioconjug Chem 18:2061-7. 2007.... - Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generatorsChristophe Antczak
Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Bioconjug Chem 17:1551-60. 2006..The excretion mechanisms of radiolabeled fragments seem to constitute a major limiting step in the chain of events leading to their clearance... - Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2Matthias Miederer
Departments of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 10:6985-92. 2004..The (225)Ac-3F8 treatment improved survival 2-fold from 16 to 34 days (P = 0.01). In conclusion, in vivo alpha generators targeted by 3F8 warrant additional study as a possible new approach to the treatment of carcinomatous meningitis... - Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubesAlessandro Ruggiero
Department of Medicine and Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Int J Nanomedicine 5:783-802. 2010..These data have implications that support further imaging and radiotherapy studies using a SWCNT-based platform and focusing on the tumor vessels as the target... - Targeted actinium-225 in vivo generators for therapy of ovarian cancerPaul E Borchardt
Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer Res 63:5084-90. 2003..In conclusion, i.p. administration with a (225)Ac-labeled internalizing anti-HER-2/neu antibody can extend survival significantly in a nude mouse model of human ovarian cancer at levels that produce no apparent gross toxicity... - Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumorsFreddy E Escorcia
Molecular Pharmacology and Chemistry Program, Cancer Biology and Genetics Program, and Departments of Medicine and Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
Cancer Res 70:9277-86. 2010..Moreover, targeting the vessel for killing provides an alternative mode of improving chemotherapy delivery and efficacy, potentially avoiding some of the drawbacks of targeting a highly redundant angiogenic pathway... - Actinium-225 in targeted alpha-particle therapeutic applicationsDavid A Scheinberg
Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Curr Radiopharm 4:306-20. 2011..Targeting 225Ac-drug constructs have potential in the treatment of cancer... - Conscripts of the infinite armada: systemic cancer therapy using nanomaterialsDavid A Scheinberg
Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Nat Rev Clin Oncol 7:266-76. 2010.... - Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemiaTodd L Rosenblat
Department of Medicine and the Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Clin Cancer Res 16:5303-11. 2010..This phase I/II trial was conducted to determine the maximum tolerated dose (MTD) and antileukemic effects of (213)Bi-lintuzumab, the first targeted α-emitter, after partially cytoreductive chemotherapy... - Engineered liposomes for potential alpha-particle therapy of metastatic cancerStavroula Sofou
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
J Nucl Med 45:253-60. 2004..Liposomes with encapsulated (225)Ac were developed to retain the potentially toxic daughters at the tumor site... - Design and synthesis of 225Ac radioimmunopharmaceuticalsMichael R McDevitt
Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Appl Radiat Isot 57:841-7. 2002..This process has yielded several potential novel targeted 225Ac-labeled immunotherapeutic agents that may now be evaluated in appropriate model systems and ultimately in humans... - A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemiaPrabodhika R Mallikaratchy
Sloan Kettering Institute, 1275 York Ave, New York, New York 10025, USA
Nucleic Acids Res 39:2458-69. 2011..The chemically engineered aptamers, with significantly improved kinetic and biochemical features, unique specificity and desirable pharmacological properties, may be useful in biomedical applications... - Immunoreactivity assay for alpha-particle emitting monoclonal antibody constructsAnthony S Bonavia
Molecular Pharmacology and Chemistry Department, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Appl Radiat Isot 64:470-4. 2006..We have identified optimal cell fixation and immunoreactivity assay conditions and have validated them by performing the fixed-cell assay in clinical trials... - Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramersRui Rong Yuan
Molecular Pharmacology and Chemistry Program, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Blood 104:2397-402. 2004..Such an approach may allow a pathway to selective ablation of pathogenic T-cell clones ex vivo or in vivo without disturbing general immune function... - Targeted nanomaterials for radiotherapyFreddy E Escorcia
Memorial Sloan Kettering Cancer Center, Molecular Pharmacology and Chemistry Program, New York, NY 10021, USA
Nanomedicine (Lond) 2:805-15. 2007..Here, we will review some of the more common nanomaterials under investigation and their current and future applications as drug-delivery scaffolds with particular emphasis on targeted cancer radiotherapy... - Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularizationDaniel J Nolan
Cancer Genome Research Center, Cold Spring Harbor Laboratory, Woodbury, New York 11797, USA
Genes Dev 21:1546-58. 2007..Our results demonstrate that BM-derived EPCs are critical components of the earliest phases of tumor neoangiogenesis...
Research Grants
- Novel Nano-Constructs to Target and Destroy Tumor NeovasculatureMichael McDevitt; Fiscal Year: 2007....